Search results
Results from the WOW.Com Content Network
Derek Lowe is a medicinal chemist working on preclinical drug discovery in the pharmaceutical industry. Lowe has published a blog about this field, "In the Pipeline", since 2002 [ 1 ] and is a columnist for the Royal Society of Chemistry 's Chemistry World .
Future Medicinal Chemistry is a peer-reviewed medical journal covering all aspects of medicinal chemistry, including drug discovery, pharmacology, in silico drug design, structural characterization techniques, ADME-Tox investigations, and science policy, economic and intellectual property issues. It was established in 2009 and is published by ...
In 2010, the research and development cost of each new molecular entity was about US$1.8 billion. [7] In the 21st century, basic discovery research is funded primarily by governments and by philanthropic organizations, while late-stage development is funded primarily by pharmaceutical companies or venture capitalists. [8]
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may ...
A new chemical entity (NCE) is, according to the U.S. Food and Drug Administration, a novel, small, chemical molecule drug that is undergoing clinical trials or has received a first approval (not a new use) by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act. [1]
Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use.
According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.495, ranking it 27th out of 59 journals in the category "Chemistry, Medicinal" [2] and 163 out of 289 journals in the category "Biochemistry & Molecular Biology". [3] The editor-in-chief is Mike Waring (Newcastle University). [4]
ChemMedChem is a biweekly peer-reviewed scientific journal covering medicinal chemistry.It is published by Wiley-VCH on behalf of Chemistry Europe.In addition to original research in the form of full papers and shorter communications, the journal contains review-type articles (reviews, minireviews, patent reviews, essays, highlights) as well as occasional book reviews and conference reports.